Johnson & Johnson (FRA:JNJ)

Germany flag Germany · Delayed Price · Currency is EUR
165.68
+0.40 (0.24%)
Last updated: Oct 21, 2025, 4:15 PM CET
0.24%
Market Cap400.01B
Revenue (ttm)78.54B
Net Income (ttm)21.41B
Shares Outn/a
EPS (ttm)8.82
PE Ratio18.68
Forward PE17.21
Dividend4.62 (2.79%)
Ex-Dividend DateAug 26, 2025
Volume3,051
Average Volume704
Open165.90
Previous Close165.28
Day's Range165.44 - 166.60
52-Week Range129.00 - 168.00
Betan/a
RSI70.38
Earnings DateOct 14, 2025

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizo... [Read more]

Industry Pharmaceutical Preparations
Founded 1886
Employees 138,100
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol JNJ
Full Company Profile

Financial Performance

In 2024, Johnson & Johnson's revenue was $88.82 billion, an increase of 4.30% compared to the previous year's $85.16 billion. Earnings were $14.07 billion, a decrease of -59.99%.

Financial numbers in USD Financial Statements

News

Johnson & Johnson (JNJ) Reports Promising Results for Amivantamab in Cancer Study

Johnson & Johnson (JNJ) Reports Promising Results for Amivantamab in Cancer Study

2 days ago - GuruFocus

Johnson & Johnson (JNJ) Boosts Guidance Amid Strategic Unit Separation

Johnson & Johnson (JNJ) Boosts Guidance Amid Strategic Unit Separation

2 days ago - GuruFocus

Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer

Responses were rapid and durable, and tumor shrinkage was observed in 82 percent of patients New findings from this investigational study build on the strength of RYBREVANT® (amivantamab-vmjw) in non-...

2 days ago - PRNewsWire

Should You Buy, Sell or Hold J&J Stock After Robust Q3 Earnings?

JNJ's strong Q3 results, upbeat sales outlook and expanding drug pipeline highlight resilience despite Stelara LOE.

4 days ago - Nasdaq

Johnson & Johnson lawsuit explained: Families sue over baby powder cancer claims

Thousands in the UK are suing Johnson & Johnson, alleging that the company's baby powder products concealed cancer risks

4 days ago - Evening Standard

Johnson & Johnson (JNJ) Faces Legal Challenges in UK Over Talc Products

Johnson & Johnson (JNJ) Faces Legal Challenges in UK Over Talc Products

5 days ago - GuruFocus

Johnson & Johnson (JNJ) Faces Legal Challenges Over Alleged Asbestos in Baby Powder

Johnson & Johnson (JNJ) Faces Legal Challenges Over Alleged Asbestos in Baby Powder

5 days ago - GuruFocus

Johnson & Johnson faces UK lawsuit over talc cancer claim

Thousands of UK claimants have filed legal action against US pharmaceutical and cosmetics giant Johnson & Johnson alleging people diagnosed with cancers were exposed to asbestos in its talcum powder, ...

5 days ago - Yahoo

Jamison Loads Up on Johnson & Johnson (JNJ) Stock With a 39K Share Purchase

Key PointsJameson Private Wealth Management increased its JNJ position by 39,471 shares, with an estimated trade value of $6.76 million based on the quarter’s average price

5 days ago - Nasdaq

Johnson & Johnson (JNJ) Myeloma Treatment Shows Promising Trial Results

Johnson & Johnson (JNJ) Myeloma Treatment Shows Promising Trial Results

5 days ago - GuruFocus

‘When I was a child, everyone used it’: woman blames Johnson & Johnson talc for her cancer

Sue Rizzello is among thousands in UK suing the firm, which denies selling baby powder containing asbestos Thousands in UK take legal action against Johnson & Johnson over alleged talc cancer link It ...

5 days ago - The Guardian

Johnson & Johnson's Phase 3 Study Shows Promising Results for Multiple Myeloma

Johnson & Johnson's Phase 3 Study Shows Promising Results for Multiple Myeloma

5 days ago - GuruFocus

Johnson & Johnson succeeds in late-stage multiple myeloma trial

Johnson & Johnson’s Tecvayli combo meets main goal in late-stage myeloma trial. Read more here.

5 days ago - Seeking Alpha

Guru Fundamental Report for JNJ

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our Multi-Factor Investor model based on the published strategy of ...

5 days ago - Nasdaq

Johnson & Johnson (JNJ) Faces Major UK Lawsuit Over Talc Products

Johnson & Johnson (JNJ) Faces Major UK Lawsuit Over Talc Products

5 days ago - GuruFocus

Exclusive: Ulta Beauty’s new CFO is a Johnson & Johnson veteran tasked to help lead the company’s next chapter

Christopher DelOrefice will join the company on Dec. 5.

5 days ago - Fortune

ETFs to Watch Post JNJ's Q3 Earnings Surprise & Bullish Outlook

JNJ's Q3 earnings beat and raised 2025 sales outlook could lift healthcare ETFs like IHE, XLV and IYH, heavily weighted toward the drugmaker.

5 days ago - Nasdaq

TECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care

First Phase 3 study (MajesTEC-3) of an investigational combination to show benefit in PFS and OS in relapsed/refractory multiple myeloma as early as second line Independent Data Monitoring Committee (...

5 days ago - PRNewsWire

J&J hit with first U.K. lawsuits over talc-related cancer claims

Johnson & Johnson (JNJ) stock is in focus as the company faces its first UK lawsuit over allegations that its talc products caused cancer. Read more here.

5 days ago - Seeking Alpha

Thousands in UK open case against Johnson & Johnson over alleged talcum powder cancer link

High court claim says company knowingly sold product containing asbestos and ‘concealed’ risk to public Thousands of people are taking legal action against pharmaceutical company Johnson & Johnson, cl...

5 days ago - The Guardian

Thousands sue Johnson & Johnson in UK over baby powder cancer claims

Claims Johnson & Johnson ‘concealed’ the risk to the public for decades

5 days ago - Yahoo

Thousands sue Johnson & Johnson in UK over cancer claims

Johnson & Johnson (J&J) is facing legal action from thousands of people in the UK who are accusing the global healthcare giant of knowingly selling talcum powder contaminated with asbestos.

6 days ago - Sky News

Thousands in UK sue Johnson & Johnson over talcum powder cancer risks

The claim involves 3,000 people and focuses on internal memos and scientific reports, seen by the BBC.

6 days ago - BBC

J&J faces first UK lawsuits alleging its baby powder caused cancer

Johnson & Johnson is facing the first lawsuits in Britain over allegations that its talc products cause cancer, as it fights tens of thousands of similar claims in the United States.

6 days ago - Reuters